Eagle Pharmaceuticals, Inc. (EGRX)
| Market Cap | 55.06M |
| Revenue (ttm) | 257.55M |
| Net Income (ttm) | 11.95M |
| Shares Out | 12.99M |
| EPS (ttm) | 0.91 |
| PE Ratio | 4.66 |
| Forward PE | 1.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,160 |
| Open | 4.500 |
| Previous Close | 4.550 |
| Day's Range | 4.190 - 4.500 |
| 52-Week Range | 4.100 - 30.400 |
| Beta | 0.41 |
| Analysts | Sell |
| Price Target | 17.00 (+300.94%) |
| Earnings Date | May 7, 2024 |
About EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for EGRX stock is "Sell" and the 12-month stock price forecast is $17.0.
News
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versu...
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the L...
Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Fa...
Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX
NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit again...
Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of invest...
Shareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRX
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsui...
FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX
NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities l...
FEBRUARY 9 DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX
NEW YORK , Feb. 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 an...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...
SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)
NEW YORK , Feb. 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...